Antineoplastics and Immunomodulators 2024 Tender, Czech Republic - 98523598

Procurement Summary

Country : Czech Republic

Summary : Antineoplastics and Immunomodulators 2024

Deadline : 10 Apr 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 98523598

Document Ref. No. : 145435-2024

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : CZK 66560000

Purchaser's Detail

Purchaser : UNIVERSITY HOSPITAL IN PILSEN
Address: Edvarda Beneše 1128
Town: Plzeň
NUTS-Code: CZ032
Postal Code: 30100
Phone: 420 603366059
Czech Republic
Email :kozak@fnplzen.cz
URL :https://www.fnplzen.cz

Tender Details

The subject of the public contract is the supply of medicinal products intended for the therapy of serious chronic diseases in the total expected volume of 122, 952 individual doses of medicinal products.

Delivery of preva number of tasks will be carried out based on the results of the completed procurement procedure for a period of four years from the signing of the purchase contract.

Cytostatic drug containing the active ingredient cemiplimab

Ampoules containing 350 mg of cemiplimab, expected annual volume of 50 ampoules (doses); ATC L01FF06

Immune preparation containing active substance dupilumab

Ampoules containing 300 mg of dupilumab, estimated annual volume of 1, 600 ampoules (doses); ATC D11AH05

Cytostatic agent containing the active substance sacituzumab govitecan

Ampoules containing 200 mg of sacituzumab govitecan, estimated annual volume of 600 ampoules (doses); ATC L01FX17

Immune preparation with effective contentsubstances plerixafor

Ampoules containing 24 mg of plerixafor, estimated annual volume of 12 ampoules (doses); ATC L03AX16

Cytostatic agent containing the active substance isatuximab

Ampoule containing 100 mg of isatuximab, estimated annual volume of 120 ampoules (dosage); ampoule containing 500 mg isatuximab, estimated annual volumeem 100 ampoules (dosage); ATC L01FC02

Immunosuppressant containing the active substance sarilumab

Ampoule containing 200 mg of sarilumab, estimated annual volume of 90 ampoules (dose); ATC L04AC14

Immunosuppressant containing the active substance ponesimod

P.o. form containing 20 mg of ponesimod, estimated annual volume of 15, 120 is...
Document Type: Contract Notice
Reference Number: 24/24
Contract Type: supplies
Estimated Value: 66560000 - CZK
Authority Type: pub-undert-cga
Doc Title: Antineoplastika a imunomodulatory 2024
Dispatch Date: 2024-03-08
Publish Date: 2024-03-11
Submission Date: 2024-04-10

Documents

 Tender Notice